Literature DB >> 33130310

Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.

Liming Zhang1, Wei Wang2, Ruikun Wang1, Nianchao Zhang3, Hang Shang4, Yang Bi4, Da Chen4, Cuizhu Zhang1, Long Li5, Jie Yin5, Hongkai Zhang6, Youjia Cao7.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the major type of pancreatic malignancy with very poor prognosis. Despite the promising results of immune checkpoint inhibitors (ICIs) in some solid tumors, immunotherapy is less effective for PDAC due to its immunosuppressive tumor microenvironment (TME). In this report, we established an immunocompetent syngeneic PDAC model and investigated the effect of oncolytic herpes simplex virus-1 (oHSV) on the composition of TME immune cells. The oHSV treatment significantly reduced tumor burden and prolonged the survival of tumor-bearing mice. Further, by single cell RNA sequencing (scRNA-seq) and multicolor fluorescence-activated cell sorting (FACS) analysis, we demonstrated that oHSV administration downregulated tumor-associated macrophages (TAMs), especially the anti-inflammatory macrophages, and increased the percentage of tumor-infiltrating lymphocytes, including activated cytotoxic CD8+ T cells and T helper (Th)1 cells. Besides, the combination of oHSV and immune checkpoint modulators extended the lifespan of the tumor-bearing mice. Overall, our data suggested that oHSV reshapes the TME of PDAC by boosting the immune activity and leads to improved responsiveness of PDAC to immunotherapy.
Copyright © 2020 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer therapy; oncolytic herpes simplex virus; pancreatic ductal adenocarcinoma; single cell RNA sequencing; tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 33130310      PMCID: PMC7854309          DOI: 10.1016/j.ymthe.2020.10.027

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  60 in total

1.  clusterProfiler: an R package for comparing biological themes among gene clusters.

Authors:  Guangchuang Yu; Li-Gen Wang; Yanyan Han; Qing-Yu He
Journal:  OMICS       Date:  2012-03-28

2.  Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors.

Authors:  Marion Gayral; Hubert Lulka; Naima Hanoun; Coline Biollay; Janick Sèlves; Alix Vignolle-Vidoni; Hervé Berthommé; Pascal Trempat; Alberto L Epstein; Louis Buscail; Jean-Luc Béjot; Pierre Cordelier
Journal:  Hum Gene Ther       Date:  2015-01-19       Impact factor: 5.695

3.  Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development.

Authors:  A Kumanogoh; X Wang; I Lee; C Watanabe; M Kamanaka; W Shi; K Yoshida; T Sato; S Habu; M Itoh; N Sakaguchi; S Sakaguchi; H Kikutani
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

4.  Integrating single-cell transcriptomic data across different conditions, technologies, and species.

Authors:  Andrew Butler; Paul Hoffman; Peter Smibert; Efthymia Papalexi; Rahul Satija
Journal:  Nat Biotechnol       Date:  2018-04-02       Impact factor: 54.908

5.  Vav1 increases Bcl-2 expression by selective activation of Rac2-Akt in leukemia T cells.

Authors:  Ya-Juan Wan; Yin Yang; Qian-Li Leng; Bei Lan; Hui-Yan Jia; Yao-Hui Liu; Cui-Zhu Zhang; Youjia Cao
Journal:  Cell Signal       Date:  2014-05-29       Impact factor: 4.315

6.  Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy.

Authors:  H Kasuya; Y Nishiyama; S Nomoto; F Goshima; S Takeda; I Watanabe; N Nomura; T Shikano; T Fujii; N Kanazumi; A Nakao
Journal:  Cancer Gene Ther       Date:  2007-04-06       Impact factor: 5.987

7.  Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.

Authors:  Zuqiang Liu; Roshni Ravindranathan; Pawel Kalinski; Z Sheng Guo; David L Bartlett
Journal:  Nat Commun       Date:  2017-03-27       Impact factor: 14.919

8.  Cancer-Associated Fibroblasts in Pancreatic Cancer: Should They Be Deleted or Reeducated?

Authors:  Chao Qu; Qing Wang; Zhiqiang Meng; Peng Wang
Journal:  Integr Cancer Ther       Date:  2018-08-23       Impact factor: 3.279

Review 9.  The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.

Authors:  Ibrahim Ragab Eissa; Itzel Bustos-Villalobos; Toru Ichinose; Shigeru Matsumura; Yoshinori Naoe; Noriyuki Miyajima; Daishi Morimoto; Nobuaki Mukoyama; Wu Zhiwen; Maki Tanaka; Hitoki Hasegawa; Seiji Sumigama; Branko Aleksic; Yasuhiro Kodera; Hideki Kasuya
Journal:  Cancers (Basel)       Date:  2018-09-26       Impact factor: 6.639

Review 10.  Molecular mechanisms underlying Th1-like Treg generation and function.

Authors:  Alexandra Kitz; Margarita Dominguez-Villar
Journal:  Cell Mol Life Sci       Date:  2017-06-17       Impact factor: 9.261

View more
  10 in total

1.  m6A regulators are differently expressed and correlated with immune response of pancreatic adenocarcinoma.

Authors:  Tao Zhang; Ping Sheng; Yuting Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-03       Impact factor: 4.553

Review 2.  Cutting both ways: the innate immune response to oncolytic virotherapy.

Authors:  David Mealiea; J Andrea McCart
Journal:  Cancer Gene Ther       Date:  2021-08-27       Impact factor: 5.854

Review 3.  An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer.

Authors:  Maryum Nisar; Rehan Zafar Paracha; Sidra Adil; Sumair Naseem Qureshi; Hussnain Ahmed Janjua
Journal:  Front Oncol       Date:  2022-05-24       Impact factor: 5.738

4.  CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.

Authors:  Ruikun Wang; Jingru Chen; Wei Wang; Zhuoqian Zhao; Haoran Wang; Shiyu Liu; Fan Li; Yajuan Wan; Jie Yin; Rui Wang; Yuanke Li; Cuizhu Zhang; Hongkai Zhang; Youjia Cao
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751

5.  A New Strategy to Identify ceRNA-Based CCDC144NL-AS1/SERPINE1 Regulatory Axis as a Novel Prognostic Biomarker for Stomach Adenocarcinoma via High Throughput Transcriptome Data Mining and Computational Verification.

Authors:  Zhihong Huang; Xinkui Liu; Chao Wu; Shan Lu; Stalin Antony; Wei Zhou; Jingyuan Zhang; Zhishan Wu; Yingying Tan; Xiaotian Fan; Leiming You; Zhiwei Jing; Jiarui Wu
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

Review 6.  Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.

Authors:  Elizabeth Appleton; Jehanne Hassan; Charleen Chan Wah Hak; Nanna Sivamanoharan; Anna Wilkins; Adel Samson; Masahiro Ono; Kevin J Harrington; Alan Melcher; Erik Wennerberg
Journal:  Front Immunol       Date:  2021-10-18       Impact factor: 7.561

Review 7.  Mesenchymal stem/stromal cells in cancer therapy.

Authors:  Tianxia Lan; Min Luo; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2021-11-17       Impact factor: 17.388

8.  Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model.

Authors:  Sijia Tang; Lei Shi; Breona T Luker; Channen Mickler; Bhavana Suresh; Gregory B Lesinski; Daping Fan; Yuan Liu; Ming Luo
Journal:  Virol J       Date:  2022-02-23       Impact factor: 4.099

9.  Fibroblast Activation Protein-Alpha is a Prognostic Biomarker Associated With Ferroptosis in Stomach Adenocarcinoma.

Authors:  Zejian Lyu; Yafang Li; Dandan Zhu; Sifan Wu; Fei Hu; Yu Zhang; Yong Li; Tieying Hou
Journal:  Front Cell Dev Biol       Date:  2022-03-14

10.  GRHL2 Expression Functions in Breast Cancer Aggressiveness and Could Serve as Prognostic and Diagnostic Biomarker for Breast Cancer.

Authors:  Xiaoyu Bai; Yue Li; Yanlei Li; Fan Li; Na Che; Chunsheng Ni; Nan Zhao; Xiulan Zhao; Tieju Liu
Journal:  Clin Med Insights Oncol       Date:  2022-07-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.